NEW YORK (GenomeWeb News) — Digene this week said it has extended by four years a three-year agreement with Quest Diagnostics under which Quest will market Digene’s test for human papillomavirus.
Digene will continue to supply Quest’s labs with the instrumentation and reagents for HPV testing, the company said.
Digene also said that Quest will “continue its efforts with Digene to educate and promote HPV screening along with the Pap test to its customer base of hospitals, physicians, and other healthcare providers.”
The test is used to detect HPV, which is “the recognized cause of cervical cancer,” and has been approved by the US Food and Drug Administration for use along with a Pap test in women aged 30 and older as a cervical cancer screen, Digene said.
Financial terms of the agreement were not released.